Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from ...

BARCELONA, Spain, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived ...

Grifols (GRFS) has established a partnership with the Biomedical Advanced Research and Development Authority to test investigational ocular ...

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare ...

Grifols SA has entered into a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to ...

Episode three of The Leaders’ Room’s season two features Grifols Ireland lead, Shane O’Brien. This series is created in partnership with IDA Ireland.

A successful preclinical study of this potentially innovative therapeutic could lead to an FDA license for one of the first medical treatments for sulfur mustard ocular injury Grifols also plans to ...

Grifols, S.A. (NASDAQ:GRFS) is a company that unfortunately has not been performing as I expected it to. My position is in the green, but this has more to do with FX and me adding shares below my ...

BARCELONA, Spain, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

BARCELONA - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company, has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to evaluate ...

BARCELONA - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company, has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to evaluate ...